Two Pandion vets jump back into the startup world, this time using machine learning to build better immunology drugs
As her days as a Merck employee dwindled down and the uncertain next step of her career stared her in the face, Jo Viney felt a sense of a job left undone. Not at Merck, mind you, but at Pandion — the immunology biotech the veteran drug developer co-founded and helped guide into Merck’s arms for $1.85 billion in early 2021.
At first, Viney leaned toward returning to “big biotech” — a route reflected in her past positions at Genentech, Biogen and Amgen — but when the opportunity came to take another stab at a startup, she knew the opportunity was too good to pass.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
